Navigation Links
Bayer CropScience Looks to the Future of Farming at 2013 Farm Progress Show
Date:8/29/2013

n early next year and will focus on Integrated Pest Management and the multiple factors impacting the health of honey bees. It is the second established by the company to promote bee health. In 2012, a global Bayer Bee Care Center was established at the joint headquarters campus of Bayer CropScience and Bayer Animal Health in Monheim, Germany.

  •     The company recently purchased nearly 70 acres near its campus in Research Triangle Park to allow for future expansion.
  • Bayer executives also shared examples of Bayer CropScience innovation, including:

    •     New soybean trait Balance® GT, which is tolerant to both glyphosate and to Balance® Bean, an isoxaflutole-based herbicide. This double herbicide-tolerant trait stack is packed in high-yielding elite genetics for premium performance.
    •     Weed management tools—for example Liberty Link® with Liberty® herbicide, an innovation in traits across a variety of crops such as canola, cotton, corn and soybeans?allow growers to manage weed pressures with the varieties that fit their growing conditions.
    •     Poncho®/VOTiVO® seed treatment, which combines an insecticide and a biological mode of action with a unique bacteria strain that lives and grows with young roots to protect soybeans and other crops.
    •     Fully-automated seed treatment system On Demand™ and the opening of 10 global SeedGrowth™ centers to support and train seed treaters on, for example, how to achieve exact treatment dosages and reduce dust abrasion with coatings.

    They also discussed flagship brands, such as Corvus® pre-emergence corn herbicide, which provides consistent one-pass grass and broadle
    '/>"/>

    Source: PRWeb
    Copyright©2012 Vocus, Inc.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Bayer HealthCares Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon
    2. Bayer Advanced(TM) Sets Sights on New Partnerships in 2013
    3. QIAGEN and Bayer HealthCare Partner to Develop Companion Diagnostics to Guide Treatment Decisions for Targeted Cancer Therapies
    4. Bayer CropScience Announces LibertyLink LinkUp Offer Increased for 2013 Season
    5. Bayer Bee Care Center Helps Solve Bee Health’s Toughest Challenges
    6. Growers Choose the Bayer CropScience LibertyLinkSystem for Yield and Performance
    7. Bayer CropScience Provides a Glimpse of SeedGrowth™ Innovation
    8. Bayer CropScience Launches Third Annual Young Farmer Sustainability Award Program
    9. Bayer CropScience Hosts Inaugural Vegetable Future Forum in Monheim
    10. Bayer CropScience Announces Registration for use of Alion on Grapes in California
    11. Bayer CropScience Purchases Land Adjacent to its Research Triangle Park Headquarters
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
    (Date:5/21/2015)... 21, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. ... medicine company focused on the development of autologous ... at the International Society for Cellular Therapy (ISCT) ... tendinosis currently in a Phase 1/2 clinical trial.  ... from 5:30 PM to 7:00 PM local ...
    (Date:5/20/2015)... , May 20, 2015 ... presented preliminary data demonstrating the ability of the ... fibrosis (IPF) from other interstitial lung diseases (ILDs) ... the classifier,s potential to help thousands of patients ... ambiguity in IPF diagnosis – a frequent challenge ...
    (Date:5/20/2015)... , May 19, 2015 Research and Markets ... of the "Global Cell Therapy Market Outlook 2020 ... of cell therapy in tissue and regenerative medicine is ... no other options which could help in the growth ... this segment but they are unable to form new ...
    Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3
    (Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
    (Date:5/8/2015)... Synaptics Inc. (NASDAQ: SYNA ), the leading ... the executive management team will present at the following investor ... Telecom Conference Date: May 18, 2015 Time: 10:40am ... Cowen and Company Technology, Media & ... The New York Palace Hotel, New York, NY ...
    (Date:5/6/2015)... 2015 LifeBEAM, a developer of bio-sensing technology, ... today that they will expand their partnership in bio-sensing ... cycling helmet and the first joint project between the ... in order to give cyclists more style choices and ... and Lazer announced their plan to release a new ...
    Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2Synaptics to Present at Upcoming Investor Conferences 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3
    ... of the 1962 Nobel Prize with Francis Crick and Maurice ... DNA, will present "Curing Incurable Cancer" and attend other events ... the James Graham Brown Cancer Center at the University of ... 5, at the Brown Theater, 315 W. Broadway, Louisville. Admission ...
    ... early stages of a major cause of failure in joint ... avoid additional surgery. More than 1.5 million total joint replacement ... is 90 per cent, almost 10 per cent of implants ... journal Molecular Pharmaceutics . Dong Wang and colleagues ...
    ... do not rely on oxygen may have played an important ... to a theory that UChicago researcher Albert Colman is testing ... Siberia. He has found that bacteria at the site ... that scientists must take into account as they attempt to ...
    Cached Biology News:UofL hosts address by Nobel Laureate, DNA structure co-discoverer James Watson 2Cold case: Siberian hot springs reveal ancient ecology 2Cold case: Siberian hot springs reveal ancient ecology 3
    Rabbit polyclonal to hnRNP-U...
    ... DNase I (RNase-free) (E.C. 3.1.21.1) is ... DNA and chromatin. It functions by hydrolyzing ... a 5'-phosphate and a 3'-hydroxyl group. Ambion's ... purity available and is recommended to degrade ...
    ... Agarose Gel-Digesting Preparation contains a unique β-agarose ... quantitative recovery of intact DNA and RNA ... following electrophoresis in TAE, TBE, MOPS, or ... directly in the TAE, TBE, MOPS, and ...
    ... sheer in-house demand is causing shortages in your ... This can cause unwanted distractions, problems and delays. ... your hard work and endeavour! Bring us your ... market it internationally. We work under ISO 9001 ...
    Biology Products: